scholarly journals Cyclosporin A Provides No Sustained Immunologic Benefit to Persons with Chronic HIV‐1 Infection Starting Suppressive Antiretroviral Therapy: Results of a Randomized, Controlled Trial of the AIDS Clinical Trials Group A5138

2006 ◽  
Vol 194 (12) ◽  
pp. 1677-1685 ◽  
Author(s):  
Michael M. Lederman ◽  
Laura Smeaton ◽  
Kim Y. Smith ◽  
Benigno Rodriguez ◽  
Minya Pu ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Randomized Controlled Trial ◽  
Antiretroviral Therapy ◽  
Cyclosporin A ◽  
Controlled Trial ◽  
Randomized Controlled ◽  
Aids Clinical Trials ◽  
Hiv 1

scholarly journals Switch to second-line versus continued first-line antiretroviral therapy for patients with low-level HIV-1 viremia: An open-label randomized controlled trial in Lesotho

PLoS Medicine ◽  
2020 ◽  
Vol 17 (9) ◽  
pp. e1003325
Author(s):  
Alain Amstutz ◽  
Bienvenu Lengo Nsakala ◽  
Fiona Vanobberghen ◽  
Josephine Muhairwe ◽  
Tracy Renée Glass ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Antiretroviral Therapy ◽  
Controlled Trial ◽  
Second Line ◽  
First Line ◽  
Open Label ◽  
Low Level ◽  
Randomized Controlled ◽  
Hiv 1

Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial

AIDS ◽  
2006 ◽  
Vol 20 (18) ◽  
pp. 2305-2313 ◽  
Author(s):  
Abdoulaye Ouedraogo ◽  
Nicolas Nagot ◽  
Laurence Vergne ◽  
Issouf Konate ◽  
Helen A Weiss ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Antiretroviral Therapy ◽  
Controlled Trial ◽  
Randomized Controlled ◽  
Hiv 1

TILT: a randomized controlled trial of interruption of antiretroviral therapy with or without interleukin-2 in HIV-1 infected individuals

AIDS ◽  
2008 ◽  
Vol 22 (6) ◽  
pp. 737-740 ◽  
Author(s):  
Brian Angus ◽  
Fiona Lampe ◽  
Guiseppe Tambussi ◽  
Claudine Duvivier ◽  
Christine Katlama ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Antiretroviral Therapy ◽  
Controlled Trial ◽  
Interleukin 2 ◽  
Randomized Controlled ◽  
Hiv 1

scholarly journals Mitochondrial Reprogramming—What Is the Benefit of Hypothermic Oxygenated Perfusion in Liver Transplantation?

2021 ◽  
Vol 2 (2) ◽  
pp. 149-161
Author(s):  
Rebecca Panconesi ◽  
Mauricio Flores Carvalho ◽  
Matteo Mueller ◽  
Philipp Dutkowski ◽  
Paolo Muiesan ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Clinical Trials ◽  
Randomized Controlled Trial ◽  
Cohort Studies ◽  
Controlled Trial ◽  
Machine Perfusion ◽  
Randomized Controlled ◽  
Hypothermic Perfusion ◽  
Underlying Mechanisms ◽  
Circulatory Death

Although machine perfusion is a hot topic today, we are just at the beginning of understanding the underlying mechanisms of protection. Recently, the first randomized controlled trial reported a significant reduction of ischemic cholangiopathies after transplantation of livers donated after circulatory death, provided the grafts were treated with an endischemic hypothermic oxygenated perfusion (HOPE). This approach has been known for more than fifty years, and was initially mainly used to preserve kidneys before implantation. Today there is an increasing interest in this and other dynamic preservation technologies and various centers have tested different approaches in clinical trials and cohort studies. Based on this, there is a need for uniform perfusion settings (perfusion route and duration), and the development of general guidelines regarding the duration of cold storage in context of the overall donor risk is also required to better compare various trial results. This article will highlight how cold perfusion protects organs mechanistically, and target such technical challenges with the perfusion setting. Finally, the options for viability testing during hypothermic perfusion will be discussed.

Sign in / Sign up

Export Citation Format

Share Document